Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) EBITDA Margin (2018 - 2025)

10x Genomics' EBITDA Margin history spans 8 years, with the latest figure at 11.77% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1843.0% year-over-year to 11.77%; the TTM value through Dec 2025 reached 9.49%, up 2237.0%, while the annual FY2025 figure was 9.49%, 2237.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 11.77% at 10x Genomics, up from 21.64% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 17.42% in Q2 2025 and bottomed at 61.7% in Q3 2023.
  • The 5-year median for EBITDA Margin is 27.31% (2024), against an average of 26.36%.
  • The largest annual shift saw EBITDA Margin soared 35735bps in 2021 before it crashed -4554bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 12.97% in 2021, then decreased by -14bps to 14.78% in 2022, then tumbled by -103bps to 30.0% in 2023, then dropped by -1bps to 30.2% in 2024, then skyrocketed by 61bps to 11.77% in 2025.
  • Per Business Quant, the three most recent readings for TXG's EBITDA Margin are 11.77% (Q4 2025), 21.64% (Q3 2025), and 17.42% (Q2 2025).